Advances in Radiotherapy for Glioblastoma and IDH-Mutant High-Grade Astrocytoma: A Biological and Mechanistic Perspective

Glioblastoma (GBM) and IDH-mutant high-grade astrocytoma remain therapeutically challenging. Historical GBM chemoradiation trials reported median overall survival of approximately 15–17 months; contemporary outcomes vary with molecular features, patient selection, and additional therapies. The 60 Gy in 30 fractions partial-brain regimen remains the reference standard for fit patients with newly diagnosed GBM. This narrative review examines radiotherapy based on its underlying biology, distinguishing GBM from IDH-mutant astrocytoma under the WHO molecular framework. It links DNA damage, cell-death programs, and radiation-induced immune signaling to the treatment response and DNA repair, stemness, hypoxia, and the microenvironment to resistance. These mechanisms motivate DNA-damage-response inhibitors, molecularly matched radiosensitizers, and immunotherapy combinations. Tumor treating fields are considered as an adjunctive non-ionizing modality. Proton therapy, FLASH, and MRI-guided adaptive radiotherapy are evaluated for their rationale and normal-tissue effects. Neurocognitive injury is discussed alongside the limitations of proposed hippocampal-sparing objectives. Personalization requires molecular selection and mechanism-matched treatment, with the clinical validation of benefits beyond dosimetry or imaging alone.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-11-19
DOI
https://doi.org/10.3390/cancers18223698
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Advances in Radiotherapy for Glioblastoma and IDH-Mutant High-Grade Astrocytoma: A Biological and Mechanistic Perspective

Fatemeh Fekrmandi, Arnab Chakravarti
Cancers
Glioma Diagnosis and Treatment
article

Advances in Radiotherapy for Glioblastoma and IDH-Mutant High-Grade Astrocytoma: A Biological and Mechanistic Perspective

Fatemeh Fekrmandi, Arnab Chakravarti
article en

Abstract

Glioblastoma (GBM) and IDH-mutant high-grade astrocytoma remain therapeutically challenging. Historical GBM chemoradiation trials reported median overall survival of approximately 15–17 months; contemporary outcomes vary with molecular features, patient selection, and additional therapies. The 60 Gy in 30 fractions partial-brain regimen remains the reference standard for fit patients with newly diagnosed GBM. This narrative review examines radiotherapy based on its underlying biology, distinguishing GBM from IDH-mutant astrocytoma under the WHO molecular framework. It links DNA damage, cell-death programs, and radiation-induced immune signaling to the treatment response and DNA repair, stemness, hypoxia, and the microenvironment to resistance. These mechanisms motivate DNA-damage-response inhibitors, molecularly matched radiosensitizers, and immunotherapy combinations. Tumor treating fields are considered as an adjunctive non-ionizing modality. Proton therapy, FLASH, and MRI-guided adaptive radiotherapy are evaluated for their rationale and normal-tissue effects. Neurocognitive injury is discussed alongside the limitations of proposed hippocampal-sparing objectives. Personalization requires molecular selection and mechanism-matched treatment, with the clinical validation of benefits beyond dosimetry or imaging alone.

CancersVol. 18(22)
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US), The Ohio State University (US)
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon